Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $13.2 million.

  • Catalyst Pharmaceuticals' Change in Accured Expenses fell 3394.69% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year decrease of 4758.18%. This contributed to the annual value of $53.8 million for FY2024, which is 82841.38% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $13.2 million for Q3 2025, which was down 3394.69% from $8.3 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' 5-year Change in Accured Expenses high stood at $20.0 million for Q3 2024, and its period low was -$7.0 million during Q1 2021.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Change in Accured Expenses value was $6.4 million (recorded in 2021), while the average stood at $5.3 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 31677.23% in 2023, then surged by 44987.61% in 2024.
  • Catalyst Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $6.4 million in 2021, then skyrocketed by 78.78% to $11.5 million in 2022, then dropped by 28.82% to $8.2 million in 2023, then grew by 8.67% to $8.9 million in 2024, then surged by 48.78% to $13.2 million in 2025.
  • Its last three reported values are $13.2 million in Q3 2025, $8.3 million for Q2 2025, and -$2.6 million during Q1 2025.